In a union of two of the hottest trends in the US biopharma world, ICER is teaming up with a high-profile company to integrate real-world evidence in their assessment of treatment value. The drug pricing watchdog - formally the Institute for Clinical and Economic Review - said it will utilize the Aetion Evidence Platform® in "select upcoming assessments."
Read More
Read More